
viewPropanc Biopharma, Inc.
Propanc Biopharma appoints Ralf Brandt to scientific advisory board as it develops cancer patent
Propanc Biopharma Inc (OTCMKTS:PPCB) chief executive officer James Nathanielsz speaks to Procative Investors about the company's recent appointment of Dr Ralf Brandt to its scientific advisory board.
The company is developing patents for cancer treatment that focuses on solid tumours, using its lead product PRP, and recently received a notice of allowance for its US patent formula.
Nathanielsz says: "This is quite an exciting development because in the US, biologicals, especially ones that are naturally derived, are quite often hard to patent.
"We've been able to identify claims that we believe were novel and inventive and the US Patent and Trademark Office agreed - this is probably the highest level of protection needed in the biggest market in the world."
Quick facts: Propanc Biopharma, Inc.
Price: 0.2517 USD
OTCQB:PPCB
Market: OTCQB
Market Cap: $330.11 k
Follow
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
FOR OUR FULL DISCLAIMER CLICK HEREMost read
Tech
Google’s co-founders step down from CEO and president role at parent Alphabet
3 days, 15 hours ago
Health
Imugene’s immunotherapy strategy given stamp of approval in oversubscribed...
5 days, 20 hours ago
Tech
Expedia CEO and CFO forced to resign after clashing with board Chairman...
2 days, 12 hours ago